- Stocks
- Healthcare
- NASDAQ: BMRN

Price (delayed)

$84.765

Market cap

$16.1B

P/E Ratio

77.77

Dividend/share

N/A

EPS

$1.09

Enterprise value

$16.44B

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and

Biomarin Pharmaceutical's EPS has surged by 195% YoY and by 22% QoQ

The net income has surged by 187% year-on-year and by 23% since the previous quarter

BMRN's quick ratio is down by 47% year-on-year but it is up by 7% since the previous quarter

What are the main financial stats of BMRN

Market
Valuations
Earnings

Shares outstanding

189.88M

Market cap

$16.1B

Enterprise value

$16.44B

Price to earnings (P/E)

77.77

Price to book (P/B)

3.15

Price to sales (P/S)

6.48

EV/EBIT

64.57

EV/EBITDA

45.68

EV/Sales

6.65

Revenue

$2.47B

EBIT

$254.53M

EBITDA

$359.85M

Free cash flow

$191.82M

Per share
Balance sheet
Liquidity

EPS

$1.09

Free cash flow per share

$1.02

Book value per share

$26.89

Revenue per share

$13.09

TBVPS

$33.87

Total assets

$6.87B

Total liabilities

$1.8B

Debt

$1.09B

Equity

$5.07B

Working capital

$1.9B

Debt to equity

0.21

Current ratio

2.74

Quick ratio

1.55

Net debt/EBITDA

0.95

Margins
Efficiency
Dividend

EBITDA margin

14.6%

Gross margin

79.2%

Net margin

8.3%

Operating margin

7.6%

Return on assets

3%

Return on equity

4.2%

Return on invested capital

4.5%

Return on capital employed

4.4%

Return on sales

10.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Biomarin Pharmaceutical stock price performed over time

Intraday

-0.64%

1 week

-1.31%

1 month

1.18%

1 year

-3.37%

YTD

-12.09%

QTD

2.96%

How have Biomarin Pharmaceutical's revenue and profit performed over time

Revenue

$2.47B

Gross profit

$1.96B

Operating income

$187.21M

Net income

$205.46M

Gross margin

79.2%

Net margin

8.3%

The net income has surged by 187% year-on-year and by 23% since the previous quarter

The net margin has soared by 152% year-on-year and by 20% since the previous quarter

The operating income has surged by 151% year-on-year and by 18% since the previous quarter

Biomarin Pharmaceutical's operating margin has soared by 124% YoY and by 17% from the previous quarter

What is Biomarin Pharmaceutical's growth rate over time

What is Biomarin Pharmaceutical stock price valuation

P/E

77.77

P/B

3.15

P/S

6.48

EV/EBIT

64.57

EV/EBITDA

45.68

EV/Sales

6.65

Biomarin Pharmaceutical's EPS has surged by 195% YoY and by 22% QoQ

BMRN's P/E is 63% below its 5-year quarterly average of 211.2 and 33% below its last 4 quarters average of 117.5

The stock's price to book (P/B) is 19% less than its 5-year quarterly average of 3.9 and 7% less than its last 4 quarters average of 3.4

The equity has grown by 9% YoY and by 2.5% from the previous quarter

BMRN's price to sales (P/S) is 20% less than its 5-year quarterly average of 8.1 and 9% less than its last 4 quarters average of 7.2

The revenue has grown by 14% YoY and by 2.2% from the previous quarter

How efficient is Biomarin Pharmaceutical business performance

Biomarin Pharmaceutical's ROIC has soared by 181% YoY and by 25% from the previous quarter

BMRN's return on assets has surged by 173% year-on-year and by 20% since the previous quarter

The ROE has soared by 163% YoY and by 20% from the previous quarter

Biomarin Pharmaceutical's return on sales has surged by 151% YoY and by 21% QoQ

What is BMRN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BMRN.

How did Biomarin Pharmaceutical financials performed over time

BMRN's quick ratio is down by 47% year-on-year but it is up by 7% since the previous quarter

The company's current ratio fell by 42% YoY but it rose by 9% QoQ

The debt is 79% smaller than the equity

The equity has grown by 9% YoY and by 2.5% from the previous quarter

BMRN's debt to equity is down by 9% year-on-year and by 4.5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.